Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short term Debt (2020 - 2023)

Historic Short term Debt for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q1 2023 value amounting to $1.1 million.

  • Mirum Pharmaceuticals' Short term Debt fell 4539.08% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 4539.08%. This contributed to the annual value of $1.1 million for FY2022, which is 4539.08% down from last year.
  • Mirum Pharmaceuticals' Short term Debt amounted to $1.1 million in Q1 2023, which was down 4539.08% from $1.1 million recorded in Q4 2022.
  • In the past 5 years, Mirum Pharmaceuticals' Short term Debt registered a high of $2.2 million during Q2 2021, and its lowest value of $847000.0 during Q3 2021.
  • Its 4-year average for Short term Debt is $1.5 million, with a median of $1.5 million in 2020.
  • Examining YoY changes over the last 5 years, Mirum Pharmaceuticals' Short term Debt showed a top increase of 11462.37% in 2022 and a maximum decrease of 4539.08% in 2022.
  • Over the past 4 years, Mirum Pharmaceuticals' Short term Debt (Quarter) stood at $1.3 million in 2020, then surged by 57.91% to $2.0 million in 2021, then tumbled by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
  • Its Short term Debt stands at $1.1 million for Q1 2023, versus $1.1 million for Q4 2022 and $1.8 million for Q3 2022.